Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 143

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 143
---
000 iterations.

    F-25

The
following table summarizes the changes in the derivative liabilities:

Schedule of Derivative Liabilities 

    Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

    Warrants  
    Alto Accelerated Feature 
  
    Balance - December 31, 2022 
    $—  
    $— 
  
    Addition of new derivative 
     1,189,000  
     1,442,000 
  
    Gain on change in fair value 
     (778,340) 
     (1,438,148)
  
    Balance - December 31, 2023 
     410,660  
     3,852 
  
    Addition of new derivatives 
     166,558  
     — 
  
    Gain on change in fair value 
     (551,937) 
     (3,852)
  
    Balance - December 31, 2024 
    $25,281  
    $— 

Note
8 – Commitments and Contingencies

On
December 16, 2024, the Company entered into a sponsored research agreement (the “Sponsored Research Agreement”) with the
Regents of the University of California, on behalf of its San Francisco campus (the “UCSF”), pursuant to which UCSF’s
employee will conduct research on a project entitled “Investigation of 18F-fluorodeboronation method for PSMA targeting ligand
radiolabeling and evaluation in prostate cancer models” (the “Research Program”). Under the terms of the Sponsored
Research Agreement, the Company will bear the total cost of $0.3 million of the Research Program and has an exclusive license to the
intellectual property underlying the research. This Sponsored Research Agreement will be effective for a period of one year and may be
extended by written mutual consent of the parties. During the year ended December 31, 2024, the Company made no payments nor incurred
any costs under the Sponsored Research Agreement.

Note
9 – Business Segment Information

The
Company operates as one operating segment with a focus on products designed to address the limitations of the current cancer therapies
as well as to extend to the new applications of radiation therapy. The CEO, as our chief operating decision maker (CODM), manages and
allocates resources to the operations of the Company on a consolidated basis, considering primarily research and development expenditures,
cash burn and net loss